Kidney

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

New treatment option for prostate cancer shows successful outcomes

Retrieved on: 
Saturday, March 23, 2024
Disease, Radiation, Cryotherapy, Hatred, Collateral damage, MRI, Prostate cancer, Average revenue per user, Urology, Heat, FASR, Risk, Patient, Lung, Neoplasm, Research, Cancer, Calcification, Standard of care, Radiology, Prostate, Society, Urinary incontinence, Kidney, Erectile dysfunction, PCA, PSA, UCLA, Urethra, Medical imaging

FAIRFAX, Va., March 23, 2024 /PRNewswire/ -- A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City.

Key Points: 
  • "Prostate cancer is the most common form of cancer in men, affecting one in eight men in their lifetimes.
  • According to Dr. Raman, "This image-guided therapy maximizes our ability to kill cancer cells while minimizing collateral damage to the prostate to achieve the ultimate trifecta in prostate cancer treatment: full local cancer control while maintaining urinary continence and potency.
  • The latter are the complications of most prostate cancer therapies that patients hate and often result from a lack of precision in treatment monitoring."
  • Abstract #135 : Five-year outcomes after MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer.

Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Retrieved on: 
Friday, March 22, 2024
Inclusion, Fresenius Medical Care, Letter, Science Based Targets initiative, Kidney, Patient, UN Women, Climate, Diversity, Science, Woman, Patient satisfaction, Annual report, The Annual Report, Dialysis, FME, BAD, German, Paris Agreement

Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.

Key Points: 
  • Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.
  • Helen Giza, CEO and Chair of the Management Board of Fresenius Medical Care AG, said: "The year 2023 was a transformative one for Fresenius Medical Care, as we set out to achieve important structural, operational, and cultural changes.
  • The 2023 Annual Report summarizes Fresenius Medical Care's steps to successfully deliver on the transformation and contains Fresenius Medical Care's Non-financial Group Report, providing a comprehensive overview of its progress of sustainability activities and achievements in three strategic focus areas:
    Enhancing quality care and access to health care: In about 4,000 dialysis clinics in around 50 countries worldwide, Fresenius Medical Care provided care for over 332,000 patients in 2023.
  • It is available for download as pdf-file on the company's website: Annual reports | Fresenius Medical Care .

Environmental Litigation Group Endorses PFAS Fund Legislation Introduced by Senator Booker and Representative Soto

Retrieved on: 
Thursday, March 21, 2024
Attention, Congress, Silver, PFAS, Firefighter, Partnership, ELG, Risk, Second Continental Congress, Prostate, Smoke, Cory Booker, Dust, Cancer, Kidney, Injury, Legislation

BIRMINGHAM, Ala., March 21, 2024 /PRNewswire/ -- Today, Environmental Litigation Group, P.C. (ELG), a leader in legal representation for individuals harmed by toxic chemical exposure, is proud to endorse the proposed federal Firefighter PFAS Injury Compensation Program and Fund and calls on the United States Congress and President Joe Biden to implement and fund it as swiftly as possible.

Key Points: 
  • Introduced by Senator Cory Booker (D-NJ) and Representative Darren Soto (D-FL), this critical fund will provide full compensation to any firefighter, and their families, who have been physically injured or killed because of exposure to PFAS (per- and polyfluoroalkyl substances).
  • I thank Senator Booker and Representative Soto for their sponsorship and support."
  • ELG worked alongside Senator Booker, Representative Soto, and firefighters across the country to bring this legislation to Congress.
  • "We're grateful for Senator Booker and Representative Soto's partnership in proposing this crucial legislation," said ELG Attorney Kevin McKie.

Renowned Los Angeles Urologist Dr. Justin Houman Appointed Assistant Professor at Cedars-Sinai Medical Center

Retrieved on: 
Wednesday, March 20, 2024
Diagnosis, Peyronie's disease, Health, Infertility, Prostate cancer, Assistant, Knowledge, Research, Fertility, Patient, Suite, Male, Cedars-Sinai Medical Center, Publication, Urinary tract infection, Erectile dysfunction, LOS, Kidney, Assistant professor

LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist, as Assistant Professor in the esteemed Department of Urology. With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.

Key Points: 
  • Dr. Justin Houman, M.D., brings expertise in clinical care, research, and medical education to Cedars-Sinai's Department of Urology.
  • LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist , as Assistant Professor in the esteemed Department of Urology.
  • With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.
  • In his role as Assistant Professor, Dr. Houman will impart invaluable knowledge and mentorship to medical students, residents, and fellows in urology.

Research case series presents food as medicine as a potential treatment for lupus and other autoimmune diseases

Retrieved on: 
Tuesday, March 19, 2024
Arthralgia, Series, Brain, Xerostomia, Face, Malar rash, Kidney, Lupus, Photosensitivity, Pleurisy, Inflammation, Patient, Raw foodism, Tissue, Research, History, Grit, Hair loss, Food, Seed, MD, Quality of life, Woman, Arthritis, Chronic pain, Skin, Water, Sunlight, Scalp, Immune system, Grain boundary strengthening, Frontiers, RRP, Fatigue, Swelling, Flax, Autoimmune disease, Nut, Medicine, Dietary supplement

ST. LOUIS, March 19, 2024 /PRNewswire-PRWeb/ -- A new research case series published in Frontiers in Nutrition presents food as medicine as a potential treatment for autoimmune diseases, describing three patients with chronic autoimmune disease who showed remarkable improvement after following a predominantly raw dietary pattern high in cruciferous vegetables and omega 3 fatty acids.

Key Points: 
  • ST. LOUIS, March 19, 2024 /PRNewswire-PRWeb/ -- A new research case series published in Frontiers in Nutrition presents food as medicine as a potential treatment for autoimmune diseases, describing three patients with chronic autoimmune disease who showed remarkable improvement after following a predominantly raw dietary pattern high in cruciferous vegetables and omega 3 fatty acids.
  • All three women reported that nearly all their symptoms of both diseases resolved after just four weeks of making the dietary changes.
  • "My hope is that these cases generate greater recognition, making patients and clinicians aware of food as medicine as a treatment option for systemic lupus erythematosus and Sjögren's syndrome.
  • This case series also reflects the immediate need for more research into dietary changes as a potential treatment strategy for autoimmune disease."

International Harrington Prize Awarded to Dr. Arlene Sharpe

Retrieved on: 
Tuesday, March 19, 2024
LDL, Human papillomavirus infection, Patient, DSM-IV codes, Lecture, National Cancer Institute, Harvard University, Creativity, AAP, PD-1, Massachusetts General Hospital, Science, Diabetes, Marfan syndrome, All India Mahila Congress, Immunology, AUC, NIH, Cancer, Nivolumab, Immune system, Biochemistry, Harvard Medical School, Cervical cancer, Research, University, Antibody, ASCI, FDA, Mount Sinai Hospital, Sickle cell disease, University of Pennsylvania, PCSK9, COVID-19, Doctor of Philosophy, Biology, Kidney, Thalassemia, Johns Hopkins University, Society, Division, Leptin, Pharmaceutical industry

CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School. The award recognizes her breakthrough discoveries in immune regulation, which have established foundational principles in immunology and led to new cancer therapies that act by boosting the immune response to cancer.

Key Points: 
  • CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School.
  • Her work helped identify key pathways that restrain the activity of T lymphocytes (immune cells) to fight cancer.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers globally before selecting the 2024 Harrington Prize recipient.
  • 2023: Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their groundbreaking translational research to restore sight in inherited genetic diseases.

Panoramic Health and The Kidney and Hypertension Center Join Forces to Elevate Kidney Care in Ohio

Retrieved on: 
Tuesday, March 19, 2024
Kidney, Health, Kidney disease, Growth, KHC, Partnership, CKD, Patient, Investment, Panorama, Chronic kidney disease, ESKD, Physician, Pharmaceutical industry

TEMPE, Ariz., March 19, 2024 /PRNewswire/ -- Panoramic Health, kidney care's leading integrated provider group, is proud to announce its strategic partnership with The Kidney and Hypertension Center (KHC), the largest independent nephrology practice in Cincinnati, Ohio. This represents the first Panoramic Health integrated provider group partnership in Ohio.

Key Points: 
  • This represents the first Panoramic Health integrated provider group partnership in Ohio.
  • The alliance between Panoramic Health and KHC underscores both entities' dedication to serving the full continuum for patients and physicians through complementary, integrated service lines.
  • "We are thrilled to partner with The Kidney and Hypertension Center in Cincinnati and mark this exciting entry into Ohio," said Dr. Tarek Elsawy, Chief Executive Officer at Panoramic Health.
  • In addition, by leveraging Panoramic Health's value-based care platform, KHC taps into care management that keeps the nephrologist at the center of care delivery, leading to improved patient outcomes.

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Retrieved on: 
Tuesday, March 19, 2024
Ready4, Fresenius Medical Care, Learning, Safety, Kidney, Augmented reality, Education, Knowledge, Hospital, Emergency medicine, Augment, Intensive care medicine, Dialysis, FME, BAD, ICU, Nursing, Health, Medtech

The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.

Key Points: 
  • The glasses stream visual and acoustic recordings as users interact with the dialysis machine, providing professionals with an immersive learning experience.
  • Our innovative solution is designed to ensure that nursing staff, particularly those in Intensive Care Units, are equipped with the knowledge needed to provide high-quality and exceptional patient care," says Dr. Katarzyna Mazur-Hofsäß, member of the Management Board of Fresenius Medical Care AG and responsible for Care Enablement, Fresenius Medical Care's MedTech segment.
  • The AR glasses provide access to the Augmented Reality learning program Ready4 multiFiltratePRO AR, which Fresenius Medical Care presented today at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels.
  • Ready4 multiFiltratePRO AR has been specifically developed for use with the multiFiltratePRO, Fresenius Medical Care's Continuous Kidney Replacement Therapy system.